ESR2 and lip and oral cavity carcinoma: In a study by Abbasi et al in the Medical Research Center of Tabriz University of Medical Sciences in 2015 on the effects of HESA-A on oral cancer and its prognosis, it was shown that the erb/b2 level in patients after using HESA-A decreased from approximately 30% to 24.1% (250 mg/kg) and 3.4% (500 mg/kg).26